NEJM February 2026: Volume 394, Issue 6 – Latest Research

A new study published today, February 5, 2026, in The New England Journal of Medicine details the results of a placebo-controlled trial of enlicitide, an oral PCSK9 inhibitor. The research, appearing in Volume 394, Issue 6, pages 529-539, offers a potential new avenue for managing cholesterol levels.

Understanding PCSK9 and Cholesterol Management

PCSK9, or proprotein convertase subtilisin/kexin type 9, is a protein that plays a crucial role in regulating cholesterol levels in the blood. It works by reducing the number of receptors on liver cells that remove LDL cholesterol – often referred to as “bad” cholesterol – from the bloodstream. Inhibiting PCSK9, can lead to lower LDL cholesterol levels and a reduced risk of cardiovascular disease.

Currently, PCSK9 inhibitors are typically administered via injection. The appeal of an oral medication like enlicitide lies in its potential for increased patient convenience and adherence to treatment.

The CORALreef Lipids Investigators and the Trial Design

The trial was conducted by the CORALreef Lipids Investigators, a collaborative group of researchers. The study, as detailed in the New England Journal of Medicine publication, was designed to assess the efficacy and safety of enlicitide compared to a placebo. Specific details regarding the trial’s methodology, patient population, and primary endpoints are available in the full publication.

Key Findings from the Study

The research published today demonstrates the results of this placebo-controlled trial. The study appears in Volume 394, Issue 6 of the journal, spanning pages 529 to 539. The findings provide data on the impact of enlicitide on cholesterol levels. Further details regarding the magnitude of cholesterol reduction and the statistical significance of the results can be found within the published article.

The New England Journal of Medicine: A Leading Medical Resource

The New England Journal of Medicine is a highly respected, peer-reviewed medical journal. Established as a weekly publication, We see a primary source for new medical research, review articles, and expert opinions across a broad spectrum of medical specialties. The journal’s commitment to rigorous scientific standards makes it a trusted resource for healthcare professionals worldwide.

As of today, February 5, 2026, the journal has released Volume 394, Issue 6, alongside previous issues dating back to January 1, 2026 (Volume 394, Issue 1). Issues are published weekly, with the most recent issue containing 103 pages (pp: 521-624).

Accessing the Research

The complete article detailing the enlicitide trial is available in The New England Journal of Medicine, Volume 394, Issue 6, pages 529-539. Researchers and healthcare professionals can access the full content through the journal’s website and platforms like Ovid (https://www.ovid.com/journals/nejm/issues/2026). Life Science Network also provides access to abstracts of articles published in the journal (https://www.lifescience.net/entries/837814/a-placebo-controlled-trial-of-the-oral-pcsk9-inhib/).

OpenEvidence and Medical Information Platforms

Platforms like OpenEvidence (https://www.openevidence.com/) also feature multimedia and clinical findings from The New England Journal of Medicine, alongside content from other leading medical journals and resources like NCCN Guidelines. OpenEvidence is available on iOS and Android and is free for verified U.S. Healthcare professionals.

Looking Ahead

The publication of this study marks an important step in the development of oral PCSK9 inhibitors. While the full implications of these findings require further investigation and clinical application, the potential for a convenient, oral therapy to manage cholesterol and reduce cardiovascular risk is a promising development for patients and healthcare providers alike. The ongoing research and publication of findings in journals like The New England Journal of Medicine are essential for advancing medical knowledge and improving patient care.